The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
No nasty surprises re anticipated PBT. Overall positive I thought but caution threaded through some of the forward looking statements and wonder what the market will make of that.
Clearly I didn’t describe it as chaff, nor did I make any attempt, or suggestion, that it shouldn’t be read. Crystal clear.
For me though, the content of the Interims are far more important in connection with my investment here. Just a couple of weeks away, assuming on schedule.
Jackdaw - the critical point I’m making, is not at all that the Interims will be the latest news, when issued, more that they will be official news from a known source ie. the Company. Don’t know about you but I’ll place more of my investment decision around that.
Not against reading other material, if clearly relevant to Scancell, context provided and not just chaff lifted from the web (not suggesting this is the latter).
Can understand the disappointment that the SP is where it is. After all, we’re all here to make a profit on the Share.
However, I don’t see any part of last year as a fiasco and am pretty sure many invested here would agree. As a for instance, for anyone bemoaning the “low Genmab payment”, there are others who see that as a significant step forward for the Company.
Perhaps you should “go check the Forum” to see those alternative views.
Annual Results 15th Jan then and will reveal if PBT is above the £10M anticipated by the Board. Something closer to £10.5M would perhaps be a catalyst for the SP, particularly if accompanied by a bullish outlook statement.
Frankly, these guys at LGB have been waffling on about Scancell for many years. They probably got a Grad to phone up a large list of companies for updates and they had little idea of what the Scancell rep (whoever that actually was) was telling them and scribbled out of context bobbins.
Fake news imo. Company RNS are what matters.
Sorry TF but that’s not right. There is suggestion of funding and as I rightly say, there is no evidence of that. Scancell are not present in the list of companies who have received funding. Ask yourself why not.
JB1 - you make some interesting connections and I always enjoy reading your well thought out posts. You could be right but there is currently no evidence of NextGen funding for SCOV, whilst there is very transparent evidence for other vaccines / companies. Surely if SCOV was in the mix, it would be amongst those on the list receiving the cash? Why would it not be?